newsfilter
← Latest News
GlobeNewswire·

Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma

One new responder observed in the [212Pb]VMT01 3.0 mCi monotherapy cohort for a total of two confirmed responses out of seven (29%) treated in this cohort of the Phase 1/2a study in heavily pre-treated melanoma; further